These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 28834699)

  • 21. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.
    Patrick TA; Kranz DM; Zachary JF; Roy EJ
    Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.
    Tang P; Li L; Zhou Y; Shen CC; Kang YH; Yao YQ; Yi C; Gou LT; Yang JL
    Biotechnol Appl Biochem; 2014; 61(4):376-84. PubMed ID: 24329807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bispecific T-cell engaging antibodies for cancer therapy.
    Baeuerle PA; Reinhardt C
    Cancer Res; 2009 Jun; 69(12):4941-4. PubMed ID: 19509221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
    Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
    Riffard C; Teillaud JL
    Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy.
    Liu SQ; Grantham A; Landry C; Granda B; Chopra R; Chakravarthy S; Deutsch S; Vogel M; Russo K; Seiss K; Tschantz WR; Rejtar T; Ruddy DA; Hu T; Aardalen K; Wagner JP; Dranoff G; D'Alessio JA
    Cancer Immunol Res; 2021 Jan; 9(1):34-49. PubMed ID: 33177106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells.
    Grandjenette C; Dicato M; Diederich M
    Curr Pharm Biotechnol; 2015; 16(8):670-83. PubMed ID: 25941884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies.
    Mohan N; Ayinde S; Peng H; Dutta S; Shen Y; Falkowski VM; Biel TG; Ju T; Wu WJ
    Front Immunol; 2024; 15():1376096. PubMed ID: 38863707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors.
    Yoon A; Lee S; Lee S; Lim S; Park YY; Song E; Kim DS; Kim K; Lim Y
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32143496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bispecific antibodies for immune cell retargeting against cancer.
    Chen RP; Shinoda K; Rampuria P; Jin F; Bartholomew T; Zhao C; Yang F; Chaparro-Riggers J
    Expert Opin Biol Ther; 2022 Aug; 22(8):965-982. PubMed ID: 35485219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
    Wu Z; Guo HF; Xu H; Cheung NV
    Mol Cancer Ther; 2018 Oct; 17(10):2164-2175. PubMed ID: 30082472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.
    Taki S; Kamada H; Inoue M; Nagano K; Mukai Y; Higashisaka K; Yoshioka Y; Tsutsumi Y; Tsunoda S
    PLoS One; 2015; 10(12):e0144712. PubMed ID: 26678395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bispecific antibodies for polyclonal T-cell engagement.
    Baeuerle PA; Kufer P; Lutterbüse R
    Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
    Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
    DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
    Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD3X anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors.
    Manzke O; Fitzgerald KJ; Holliger P; Klock J; Span M; Fleischmann B; Hescheler J; Qinghua L; Johnson KS; Diehl V; Hoogenboom HR; Bohlen H
    Int J Cancer; 1999 Aug; 82(5):700-8. PubMed ID: 10417768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go.
    Shivarov V; Blazhev G
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):81-85. PubMed ID: 33900820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma.
    Zhou Y; Gou LT; Mu B; Liao WC; He J; Ma C; Yao YQ; Yang JL
    Biotechnol Lett; 2012 Jul; 34(7):1183-91. PubMed ID: 22421972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.